Riccardo Di Leo, Enrico Crispino, Doretta Cuffaro, Giuseppantonio Maisetta, Andrea Bertacca, Marta Bianchi, Giovanna Batoni, Imin Wushur, Fatema Amatur Rahman, Jan-Olof Winberg, Ingebrigt Sylte, Armando Rossello and Elisa Nuti
{"title":"铜绿假单胞菌毒力因子LasB抑制剂新型n -苯氧基氨基酸羟酸酯的鉴定。","authors":"Riccardo Di Leo, Enrico Crispino, Doretta Cuffaro, Giuseppantonio Maisetta, Andrea Bertacca, Marta Bianchi, Giovanna Batoni, Imin Wushur, Fatema Amatur Rahman, Jan-Olof Winberg, Ingebrigt Sylte, Armando Rossello and Elisa Nuti","doi":"10.1039/D5MD00393H","DOIUrl":null,"url":null,"abstract":"<p >The emergence of multidrug-resistant pathogens, particularly <em>Pseudomonas aeruginosa</em>, represents a global health concern. Among its major virulence factors, elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of <em>N</em>-benzyloxy amino acid derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound <strong>12</strong> as the most potent inhibitor (<em>K</em><small><sub>i</sub></small> = 0.92 μM), exhibiting high selectivity for LasB over human matrix metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm bacterial virulence rather than exerting bactericidal pressure.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 10","pages":" 4973-4996"},"PeriodicalIF":3.5970,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa†\",\"authors\":\"Riccardo Di Leo, Enrico Crispino, Doretta Cuffaro, Giuseppantonio Maisetta, Andrea Bertacca, Marta Bianchi, Giovanna Batoni, Imin Wushur, Fatema Amatur Rahman, Jan-Olof Winberg, Ingebrigt Sylte, Armando Rossello and Elisa Nuti\",\"doi\":\"10.1039/D5MD00393H\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The emergence of multidrug-resistant pathogens, particularly <em>Pseudomonas aeruginosa</em>, represents a global health concern. Among its major virulence factors, elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of <em>N</em>-benzyloxy amino acid derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound <strong>12</strong> as the most potent inhibitor (<em>K</em><small><sub>i</sub></small> = 0.92 μM), exhibiting high selectivity for LasB over human matrix metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm bacterial virulence rather than exerting bactericidal pressure.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 10\",\"pages\":\" 4973-4996\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00393h\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00393h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
耐多药病原体,特别是铜绿假单胞菌的出现,是一个全球性的健康问题。在其主要毒力因子中,弹性蛋白酶B (LasB)是一种锌依赖性金属蛋白酶,在宿主组织降解、免疫逃避和生物膜形成中起关键作用。用选择性抑制剂靶向LasB提供了一种很有前途的治疗策略,可以减轻细菌毒力,同时最大限度地减少耐药性发展的选择压力。本研究设计、合成了一系列n -苯氧基氨基酸衍生物,并对其对LasB的抑制活性进行了评价。基于结构优化的结果表明,化合物12是最有效的LasB抑制剂(K i = 0.92 μM),对人基质金属蛋白酶具有较高的选择性。基于细胞的实验表明,它能够抑制LasB蛋白水解活性,减少生物膜的形成,而不影响细菌的生存能力。这些发现突出了LasB抑制剂作为病原体阻滞剂的潜力,提供了一种有针对性的方法来解除细菌的毒力,而不是施加杀菌压力。
Identification of novel N-benzyloxy-amino acid hydroxamates as inhibitors of the virulence factor LasB from Pseudomonas aeruginosa†
The emergence of multidrug-resistant pathogens, particularly Pseudomonas aeruginosa, represents a global health concern. Among its major virulence factors, elastase B (LasB), a zinc-dependent metalloprotease, plays a pivotal role in host tissue degradation, immune evasion, and biofilm formation. Targeting LasB with selective inhibitors offers a promising therapeutic strategy to mitigate bacterial virulence while minimizing selective pressure for resistance development. In this study, a series of N-benzyloxy amino acid derivatives were designed, synthesized, and evaluated for their inhibitory activity against LasB. Structure-based optimization led to the identification of compound 12 as the most potent inhibitor (Ki = 0.92 μM), exhibiting high selectivity for LasB over human matrix metalloproteinases. Cell-based assays demonstrated its ability to inhibit LasB proteolytic activity and reduce biofilm formation without affecting bacterial viability. These findings highlight the potential of LasB inhibitors as pathoblockers, providing a targeted approach to disarm bacterial virulence rather than exerting bactericidal pressure.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.